Abstract
Thrombotic risk increases in elderly, therefore, the understanding of the genetic predisposition of hypercoagulability could make the difference in the prevention of venous and/or arterial thrombotic events. Laboratory evaluation of hyperfibrinogenemia, increased Factor VII levels, antiphospholipid antibodies presence and hyperhomocysteinemia are considered to have a consistent high predictivity for arterial thrombophilic diseases. Anyway, a large debate exists on the validity of testing Leiden Factor V (FV) G1691A and/or prothrombin (FII) G20210A polymorphisms in patients affected by arterial thrombotic diseases, despite of the several observations described. Here we report data strongly suggesting that at least the FII G20210A polymorphism might be considered an important risk factor for acute myocardial infarction in aged patients (55–80 years old). On the other hand, in spite of a not different genotypic and allelic distribution for the Leiden FV G1691A mutation, the presence of one or both the two polymorphisms is significantly higher among cases than in controls. In conclusion, our data suggest that FII G20210A and/or Leiden FV might be involved as risk factor for arterial disorders in about 5% of old subjects, justifying the opportunity of a genetic screening and an eventual preventive treatment, in particular in old subjects in which other and major risk factors, as hypertension and atherosclerosis, are detected.
Similar content being viewed by others
References
Billeci AM, Agnelli G, Caso V (2009) Stroke pharmacogenomics. Expert Opin Pharmacother 10(18):2947–2957
De Stefano V, Leone G (1995) Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica 80(4):344–356
De Stefano V, Finazzi G, Mannucci PM (1996) Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1 87(9):3531–3544
Forte GI, Scola L, Vaccarino L, Sanacore M, Palmeri M, La Piana S, Pipitone M, Grimaudo S, Caruso C (2009) Analysis of FV-Leiden and Facor II G20210A SNP frequencies in a group of Sicilian nonagenarians. J Nutr Health Aging 13(1):S378
Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJ, Reitsma PH (1999) The 20210 G → A mutation in the 3′ untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 104:50–54
Gemmati D, Serino ML, Moratelli S, Tognazzo S, Ongaro A, Scapoli GL (2001) Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis. Haemostasis 31(2):99–105
Kahn M (2003) Hypercoagulability as a cause of stroke in adults. South Med J 96:350–353
Kim RJ, Becker RC (2003) Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146(6):948–957
Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U (1996) Inherited thrombophilia. Thromb Haemost 76(5):651–662
Lio D, Candore G, Crivello A, Scola L, Colonna-Romano G, Cavallone L, Hoffmann E, Caruso M, Licastro F, Caldarera CM, Branzi A, Franceschi C, Caruso C (2004) Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet 41(10):790–794
Listì F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CR, Vasto S, Scafidi V, Caruso C, Candore G (2008) Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des 14(26):2678–2685
Mari D, Coppola R, Provenzano R (2008) Hemostasis factors and aging. Exp Gerontol 43(2):66–73
Mazoyer E, Ripoll L, Gueguen R, Tiret L, Collet JP, dit Sollier CB, Roussi J, Drouet L (2009) Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution. Blood Coagul Fibrinolysis 20(7):503–510
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 16:1215–1220
Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD (1996) Increased activation of the hemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 75:767–771
Ozmen F, Ozmen MM, Ozalp N, Akar N (2009) The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis. Ulus Travma Acil Cerrahi Derg 15(2):113–119
Peetz D, Schweigert R, Jachmann N, Post F, Schinzel H, Lackner KJ (2006) Method comparison of cardiac marker assays on PATHFAST, StratusCS, AxSYM, Immulite 2000, triage, elecsys and cardiac reader. Clin Lab 52(11–12):605–614
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703
Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP (1995) Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332(14):912–917
Ridker PM, Hennekens CH, Miletich JP (1999) G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 99(8):999–1004
Russo C, Girelli D, Olivieri O, Guarini P, Manzato F, Pizzolo F, Zaia B, Mazzucco A, Corrocher R (2001) G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. Circulation 103:2436–2440
Soare AM, Popa C (2010) Deficiencies of proteins C, S and antithrombin and factor V Leiden and the risk of ischemic strokes. J Med Life 3(3):235–238
Testa S, Antonucci G, Intra E, Martini G, Pedrini S, Alatri A, Bader R, Manzato F (2004) Gli screening per trombofilia. Riv Med Lab—JLM 5(2):118
Tripodi A, Mannucci PM (2001) Laboratory investigation of thrombophilia. Clin Chem 47(9):1597–1606
Van Cott E, Laposata M, Prins MH (2002) Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med 126:1281–1295
Soo L, Davidson P (2007) Laboratory testing for thrombophilia in arterial thrombosis. QML Pathology Medical PUB/MR/545, version 2
Acknowledgments
This research was supported by grants from the Ministry of Education, University and Research (Cofin. to D.L. and local initiatives to D.L.), and from Ministry of Health. G.I.F. is a Phd researcher, working on a project funded by a grant received by Italian Ministry of Education, University and Research, and this work represents an implementation of her own final report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Forte, G.I., Vaccarino, L., Palmeri, M. et al. Analysis of polymorphisms Leiden Factor V G1691A and prothrombin G20210A as risk factors for acute myocardial infarction. Biogerontology 12, 485–490 (2011). https://doi.org/10.1007/s10522-011-9358-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10522-011-9358-z